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The Study on COgnition and Prognosis in the Elderly (SCOPE) is a multi-centre, prospective,
randomized, double-blind, parallel-group study. The primary objective of SCOPE is to assess the effect of
the angiotensin II type 1 (AT1) receptor blocker, candesartan cilexetil 8–16 mg once daily, on major
cardiovascular events in elderly patients (70–89 years of age) with mild hypertension (DBP 90–99 and/or
SBP 160–179 mmHg). The secondary objectives of the study are to test the hypothesis that
antihypertensive therapy can prevent cognitive decline (as measured by the Mini Mental State
Examination, MMSE) and dementia, and to assess the effect of therapy on total mortality, myocardial
infarction (MI), stroke, renal function, and hospitalization. A total of 4964 patients from 15 participating
countries were recruited during the randomization phase of SCOPE, exceeding the target population of
4000. The mean age of the patients at enrolment was 76 years, the ratio of male to female patients was
approximately 1:2, and 52% of patients were already being treated with an antihypertensive agent at
enrolment. The majority of patients (88%) were educated to at least primary school level. At
randomization, mean sitting blood pressure values were SBP 166 mmHg and DBP 90 mmHg, and the
mean MMSE score was 28. Previous cardiovascular disease in the study population included myocardial
infarction (4%), stroke (4%) and atrial fibrillation (4%).
Men, more often than women, had a history of previous MI, stroke and atrial fibrillation. A greater
percentage of men were smokers (13% vs 6% in women) and had attended university (11% vs 3% of
women). Of the randomized patients, 21% were 80 years of age. In this age group smoking was less
common (4% vs 10% for 70–79-year-olds) and fewer had attended university (4% vs 7% for 70–79-year-
olds). The incidence of MI was similar in both age groups. However, stroke and atrial fibrillation had
occurred approximately twice as frequently in the older patients.
The patients’ mean age at baseline was similar in the participating countries, and most countries
showed the approximate 1:2 ratio for male to female patients. There was also little inter-country variation
in terms of mean SBP, DBP or MMSE score. However, there was considerable regional variation in the
percentage of patients on therapy prior to enrolment. Key words: candesartan cilexetil, cognitive function,
elderly, mild hypertension.
INTRODUCTION
Data from two large studies carried out recently, one in
the USA (NHANES III) [1] and the other in Europe
(STEPHY) [2], have confirmed Framingham study
evidence that the prevalence of hypertension and
associated cardiovascular risk increase with age in both
men and women [3]. The risk of cardiovascular events has
also been shown to be higher in elderly hypertensive
patients than in younger patients with the same level of
blood pressure [4]. Although both systolic (SBP) and
diastolic blood pressure (DBP) increase progressively up
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to approximately 60 years of age, DBP tends to decline
thereafter [3]. As a result, isolated systolic hypertension
(ISH; i.e. SBP> 140 mmHg/DBP< 90 mmHg) is the
most prevalent form of hypertension in older patients, and
SBP is a better predictor of cardiovascular events than
DBP in the elderly [5].
It is only quite recently that the benefits of treating
hypertension in the elderly have become apparent. Meta-
analysis of nine randomized, controlled trials published
over the period January 1980 to February 1992 involving
15 559 patients older than 59 years of age revealed a 36%
reduction in stroke, a 25% decrease in coronary heart
disease and a 12% reduction in all-cause mortality [6].
Several studies (STOP, SHEP, SYST-EUR and MRC
elderly) have documented the benefits of antihypertensive
therapy specifically among elderly patients with ISH, and
showed a reduction in major cardiovascular events
ranging from 17 to 40% [7–10].
Because the elderly hypertensive population may be
expected to experience more cardiovascular events
compared to a middle-aged hypertensive population, in
absolute terms—that is, in terms of the number of events
saved—antihypertensive treatment is 5–10 times more
successful in elderly patients than in middle-aged patients
with mild hypertension (Table I) [11]. Nevertheless, there
remain a number of unanswered questions concerning the
treatment of elderly patients with hypertension:
(i) The term ‘elderly’ is generally used to indicate
patients over the age of 60–65 years, but what are the
benefits of antihypertensive therapy in patients over
80 years of age?
(ii) Is the treatment of mild hypertension of benefit in the
elderly?
(iii) Since it has been shown that high blood pressure may
be associated with subsequent development of
dementia and cognitive decline in the elderly [12],
can antihypertensive therapy reduce cognitive de-
cline and the incidence of dementia?
(iv) Is angiotensin II type 1 (AT1)-receptor blockade an
effective therapeutic strategy for improving out-
comes in an elderly population with mild hyperten-
sion?
The Study on COgnition and Prognosis in the Elderly
(SCOPE) has been initiated to address these questions.
The study protocol has been described fully in a previous
issue of this journal [13]. Briefly, SCOPE is a multicentre,
prospective, randomized, double-blind, parallel-group
study designed to compare the effects of the angiotensin
II type 1 (AT1) receptor blocker, candesartan cilexetil 8–
16 mg once daily, versus placebo in elderly patients (70–
89 years of age) with mild hypertension (defined as sitting
SBP 160–179 mmHg and/or DBP 90–99 mmHg), and a
Mini-Mental State Examination (MMSE) score of 24, or
higher. Patients who remain at SBP 160 mmHg and DBP
90 mmHg are recommended open-label additional anti-
hypertensive medication, starting with HCTZ 12.5 mg.
The primary objective of SCOPE is to assess the effect
of candesartan cilexetil on major cardiovascular events.
The secondary objectives of the study are to test the
hypothesis that antihypertensive therapy can prevent
cognitive decline (as measured by the MMSE) and
dementia, and to assess the effect of therapy on total
mortality, myocardial infarction, stroke, renal function
and hospitalization. In addition, at least 1000 patients will
be assessed for quality of life and health economics data.
The study will also allow us to evaluate the possible
influence on major cardiovascular events and cognitive
function of a number of variables, including age, gender,
antihypertensive treatment, previous myocardial infarc-
tion (MI) or stroke, diabetes mellitus, smoking, body mass
index, hyperlipidaemia or treatment with lipid-lowering
drugs, and level of education.
PATIENT CHARACTERISTICS
Overall
Patients were considered eligible for enrolment in SCOPE
if they fulfilled the inclusion and exclusion criteria, as
described previously [13]. A total of 4964 patients from
15 participating countries were recruited during the
randomization phase, from 24 March 1997 to 20 January
1999, exceeding the original target population of 4000
(Table II). The mean age of the patients at enrolment was
76 years (Table III), reflecting the predominance of
patients in the younger, 70–79-year, age group (Fig. 1).
Table I. Comparison of events expected and prevented by antihypertensive treatment in elderly hypertensive patients and
in middle-aged patients with mild hypertension [11]. The values shown are the number of events/1000 patients/5 years
Middle-aged patients with mild hypertension Elderly patients with hypertension
Events Expected Prevented Expected Prevented
Cardiovascular deaths 15 4–5 120 40
Strokes 15 10 123 49
Coronary events 30 2–3 97 14
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Nevertheless, approximately one in five of the patients in
the study (n = 1053) was aged 80 years and over at
randomization. The ratio of male to female patients was
approximately 1:2 (n = 1787 and n = 3177, respectively).
At randomization, mean sitting blood pressure values
were SBP 166 mmHg and DBP 90 mmHg, and the mean
MMSE score was 28 (maximum score 30). The distribu-
tion of SBP, DBP and MMSE at randomization is shown
in Figs 2 and 3.
Just over half (52%) of all patients were receiving
antihypertensive therapy at enrolment and nearly a
quarter (22%) of the patient population was taking either
an non-steroidal anti-inflammatory drug (NSAID) or
ASA. A relatively small percentage of patients (9%)
were being treated with lipid-lowering drugs, and a
similar number were receiving psychopharmacological
drugs (8%). The occurrence of previous cardiovascular
disease in the study population was found to be relatively
low, including myocardial infarction (4%), stroke (4%)
and atrial fibrillation (4%; Table 3). The vast majority of
patients had been educated to at least primary school level
(Table 4).
Gender-based differences in baseline character-
istics. There were a number of notable differences in
the baseline characteristics between the men and
women randomized to the study. The men had a higher
occurrence of previous MI (7.8% compared with 2.7%
of women), atrial fibrillation (4.9% compared with 2.9%
of women) and stroke (4.8% compared with 3.3% of
women). A greater percentage of the men were smokers
(13.2%) compared with the women (6.1%). Differences
in the level of education between men and women were
most notable at university level, with a considerably
greater percentage of men who had attended university
(11.1%) compared with women (3.1%). The proportion
of men and women treated at enrolment was similar for
most classes of medication with the exception of
psychopharmacological drugs, which were being taken
by 11.4% of women compared with 5.6% of men.
Table II. Number of patients recruited to SCOPE per
country (total n = 4964)
Country Number
Belgium 436
Canada 68
Finland 84
France 434
Germany 617
Hungary 326
Israel 147
The Netherlands 617
Norway 418
Poland 173
Portugal 53
Spain 324
Sweden 283
UK 883
USA 101
Table III. Baseline patient characteristics (n = 4964)
Age, years (mean) 76
Male/female (%) 36/64
Smoker (%) 9
Mean sitting BP: SBP/DBP mmHg 166/90
Mean MMSE score 28
Treated at enrolment with: 52
Antihypertensive agents (%)
NSAID/ASA (%) 22
Lipid-lowering drugs (%) 9
Psychopharmacological drugs (%) 8
Previous MI (%) 4
Previous stroke (%) 4
Atrial fibrillation (%) 4
BP, blood pressure; SBP, systolic blood pressure; DBP,
diastolic blood pressure; MI, myocardial infarction.
Fig. 1. Age distribution at baseline.
Fig. 2. Distribution of systolic blood pressure (SBP) at baseline.
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Age-based differences in baseline characteristics. The
SCOPE study includes a large cohort of patients of 80
years of age and older, allowing a comparison of
baseline characteristics with patients in the decade
below them (those in the 70–79-year-old age group).
There were slightly more than twice as many smokers
amongst the 70–79-year-olds (9.8%), as amongst
patients 80 years of age and older (4.3%). Also, more of
the younger age cohort had attended university (6.5%),
compared with the older group (3.8%). The incidence of
MI was similar in both groups (4.4% in the 70–79-year-
olds and 4.9% in patients of 80 years of age and older).
However, stroke and atrial fibrillation had occurred
more frequently in the older patients (5.9% compared
with 3.3% for stroke and 5.9% compared with 3.0% for
atrial fibrillation).
Treatment with antihypertensive medication was
similar between the age groups (52.8% for the 70–79-
year-olds and 52.6% for those of 80 years of age and
older). The use of NSAIDs or ASA was also similar
between the two groups (23.2% in the 70–79-year-olds
and 23.9% in the older group). However, more patients in
the younger group used lipid-lowering agents (10.1%
compared with 6.2%), while more patients in the older
group were taking psychopharmacological drugs com-
pared with patients in younger group (12.4% compared
with 8.5%).
Regional variations
The mean age at baseline was similar within populations
from each participating country (range 74–77 years).
Most countries also showed the approximate 1:2 ratio for
male to female patients. There was little inter-country
variation in terms of mean SBP (range 160–167 mmHg),
DBP (range 86–92 mmHg) or MMSE score (range
28–29). However, considerable regional variations were
seen for the percentage of patients on therapy prior to
enrolment, including antihypertensive therapy (29–83%),
NSAID/ASA (11–49%), lipid-lowering therapy (2–24%)
and psychopharmacological therapy (1–26%).
SAMPLE SIZE AND RISK PROFILE
The original target study population was 4000, based on
the incidence of clinical events in the STOP-Hypertension
study [7]. This represents the calculated number of
patients required in order to detect a 23% reduction in the
yearly incidence of major cardiovascular events over a
2.5-year period, assuming a starting DBP of 95 mmHg.
Although the actual mean baseline DBP in SCOPE is
lower (90 mmHg), the study population is larger than
expected (4964) and has been randomized over a longer
period, thereby maintaining the power of the study.
In the baseline data, information regarding the follow-
ing risk factors (according to WHO/ISH guidelines) is
available: BP, age and gender, smoking habit, s-
cholesterol, diabetes mellitus, obesity, s-creatinine and
previous cardiovascular diseases. Thus, all patients in the
study have at least one risk factor (age >65 years), and
Grade 1 or Grade 2 hypertension.
EVALUATION OF COGNITIVE FUNCTION
The potential impact of antihypertensive therapy on
cognitive function in SCOPE patients will be assessed
using the MMSE, which has been demonstrated to be a
sensitive, specific and predictive tool in measuring
cognitive function and screening for dementia. The
MMSE score is based on 20 clearly defined questions
and tasks (which are documented in a manual developed
Fig. 3. Distribution of diastolic blood pressure (DBP) at
baseline.
Table IV. Education level (n = 4964)
Less than primary school (%) 12
Primary school (%) 43
Higher than primary school (%) 39
University (%) 6
Fig. 4. Distribution of Mini Mental State Examination (MMSE)
score at baseline.
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for this study), giving a maximum potential score of 30.
Based on a comparison of the MMSE and clinical
diagnosis of dementia in 85–88 year old patients [15]
and information from the literature [16], a decline of four
points in MMSE score has been selected to indicate
dementia. Suspected cases of dementia will be further
evaluated by dementia specialists in the study endpoint
committee.
Patients who achieve the maximum MMSE score of 30
may have cognitive function well above the upper limit of
the test, allowing them to suffer a decline in cognitive
function of equivalent to the four MMSE points defined
here, and yet remain above the maximum score level.
However, more than 60% of the patients in the SCOPE
study have an MMSE score of between 24 and 29. Hence,
any decline in cognitive function in these patients will be
within the detection range of the MMSE, suggesting that
it will be possible in this study to evaluate the potential of
antihypertensive therapy to prevent cognitive decline.
THERAPEUTIC REGIMEN
The SCOPE therapeutic regimen has been described
previously and is summarized briefly here [13]. The study
begins with an open, run-in period lasting 1–3 months,
during which patients are assessed for eligibility and those
who are already on antihypertensive therapy at enrolment
are switched to hydrochlorothiazide (HCTZ) 12.5 mg
once daily (o.d.). Subsequently, patients are randomized
to receive either candesartan cilexetil 8 mg o.d. or
matching placebo o.d. At subsequent study visits, if
SBP remains >160 mmHg, or has decreased by
<10 mmHg since the randomization visit, or DBP is
>85 mmHg, study treatment is doubled to candesartan
cilexetil 16 mg o.d. (two 8-mg tablets), or two placebo
tablets. If SBP remains 160 mmHg, or DBP is 90 mmHg,
despite treatment with two tablets, then the study protocol
recommends the initiation of additional antihypertensive
therapy, starting with HCTZ 12.5 mg.
DISCUSSION
Although the advantages of antihypertensive therapy in
elderly patients with hypertension have been clearly
demonstrated [6–11], there have been no specific studies
to date to assess the benefits of treating those with only
mildly elevated blood pressure (SBP 160–179 mmHg
and/or DBP 90–99 mmHg), in terms of preventing
cardiovascular events, stroke and the development of
cognitive dysfunction. Currently, many such patients may
go untreated, possibly resulting in earlier death, disability
or hospitalization, with the associated personal, social and
economic costs. The results of SCOPE will provide the
necessary data to determine the value of antihypertensive
therapy in this setting also in the very old patients.
The theory that elevated blood pressure may predispose
patients to the development of dementia has been
investigated in Sweden by Skoog et al. in a 15-year
longitudinal study following up subjects who were non-
demented at 70 years of age [13]. They found that patients
who developed dementia after the age of 79 had
significantly higher mean SBP and DBP at 70 years of
age than those who did not develop dementia (178/
101 mmHg vs 164/92 mmHg, respectively). The theory is
supported by sub-study results from the SYST-EUR trial
showing that antihypertensive therapy with nitrendipine
(with or without enalapril and/or hydrochlorothiazide) in
non-demented patients with isolated systolic hypertension
over the age of 60 years reduced the incidence of
dementia by 50% versus placebo over the 2-year follow-
up period (7.7 versus 3.8 cases per 1000 patient years,
p = 0.05) [17]. However, there were only 32 cases of
dementia in this study.
If it can be demonstrated that treatment of even mild
hypertension in the elderly can reduce the incidence of
dementia, this may have major consequences in terms of
the socio-economic costs of the disease. Dementia
undoubtedly takes a major toll on both the patients and
their carers, who are frequently family and friends.
Moreover, a significant positive correlation has been
demonstrated between the evolution of dementia and
healthcare costs, even in out-patients [18]. As the
population of the western world continues to age, the
prevalence of dementia and other diseases associated with
old age will almost certainly increase [19]. Although
studies analysing the economics of treating patients with
Alzheimer’s disease have considered the costs of
antidementia treatments rather than antihypertensive
therapies, it has been suggested that large savings in the
costs of caring for home-dwelling patients with Alzhei-
mer’s disease may be achievable even with interventions
that have only minor effects on patients’ cognitive status
[20].
The AT1-receptor blocker, candesartan cilexetil, is a
rational choice of antihypertensive agent for the treatment
of mild hypertension in the elderly, having a well-
established profile of dose-dependent efficacy [21] with
placebo-like tolerability [22] and long-lasting antihyper-
tensive effect from a once-daily dose [23]. Studies have
already demonstrated that candesartan cilexetil 8–16 mg
is effective and very well tolerated in elderly hypertensive
patients [24]. Importantly, AT1-receptor blockers may
help to maintain, or even improve cognitive function
through specific mechanisms other than BP reduction,
since angiotensin II has been shown to impair perfor-
mance in learning and memory paradigms [25]. The
potential benefits of AT1-receptor blockers in this setting
have already been demonstrated in animal studies
[26, 27].
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CONCLUSIONS
The baseline characteristics of the 4964 patients enrolled
in SCOPE indicate that the target population of elderly
patients with mild hypertension and with no current
dementia has been achieved. The results will provide
important data on the impact of antihypertensive therapy
with candesartan cilexetil in this population, both in terms
of cardiovascular events and cognitive function.
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